文献速递妇科

改良格拉斯哥预后评分(mGPS)在复发性卵巢癌中的验证——基于GCIG症状获益研究入组患者的分析

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
PubMed 文献 · Gynecol Oncol · 2017-10-26

本研究在GCIG症状获益研究的948例患者中,对516例有炎症标志物数据的复发性卵巢癌患者验证mGPS。mGPS为0、1、2分者分别占55%、24%、22%,中位总生存期分别为18.1、9.6、6.6个月。校正体能状态、铂敏感性和健康相关生活质量后,mGPS仍是总生存期的独立预测因子。

要点

  • mGPS 0、1、2分患者的中位总生存期分别为18.1、9.6、6.6个月。
  • 校正PS和铂敏感性后,mGPS是总生存期的独立预测因子(p<0.001)。
  • mGPS越高健康相关生活质量越差,且不依赖体能状态。

核心结论

  • 校正健康相关生活质量和临床病理因素后,mGPS是复发性卵巢癌总生存期的独立预测因子。
  • mGPS越高健康相关生活质量越差,且不依赖体能状态。
  • mGPS简单、便宜,可能适用于临床实践、临床试验患者选择和分层。

研究设计与样本

  • 对GCIG症状获益研究入组患者中516例有炎症标志物数据的复发性卵巢癌患者进行分析。
  • mGPS基于血清C反应蛋白和 albumin,评分范围0(最低)至2(最高)。
  • 健康相关生活质量采用EORTC QLQ C-30和OV-28量表测量。
  • 采用χ2趋势检验分析健康相关生活质量、体能状态与mGPS的关系,采用Cox比例风险回归评估mGPS、健康相关生活质量、临床病理因素与总生存期的关联。

主要发现

  • 516例中,200例(39%)为潜在铂敏感复发性卵巢癌且接受≥3线化疗,316例(61%)为铂耐药复发性卵巢癌。
  • mGPS为0、1、2分者分别为282例(55%)、123例(24%)、111例(22%)。
  • mGPS 0、1、2分患者的中位总生存期分别为18.1、9.6、6.6个月。
  • 校正体能状态和铂敏感性后,mGPS是总生存期的独立预测因子(p<0.001)。
  • 校正躯体功能、角色功能、总体健康状况、腹部/胃肠道症状及多个临床病理因素后,mGPS仍是总生存期的预测因子(p=0.02)。

临床怎么用

  • 原文结论指出mGPS简单、便宜,可能适用于临床实践、临床试验患者选择和分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS). METHODS: mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28. χ2 tests for trend were used to examine the relationship between HRQL, PS and mGPS. Cox proportional hazards regression was used to assess associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS). RESULTS: Inflammatory markers were available in 516 of 948 patients in GCIG SBS. 200(39%) had potentially platinum sensitive ROC with ≥3 lines of chemotherapy, 316(61%) had platinum resistant ROC. 282(55%), 123(24%), 111(22%) had mGPS of 0, 1, 2, respectively. Median OS (months) was 18.1, 9.6, and 6.6 for mGPS 0, 1, and 2 respectively. mGPS was an independent predictor of OS after adjusting for PS and platinum sensitivity (p<0.001). mGPS remained a predictor of OS after adjusting for physical function, role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors (p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001). Higher mGPS was associated with worse HRQL, independent of PS. CONCLUSION: The mGPS is an independent predictor of OS in ROC after adjusting for HRQL and clinicopathological factors. Higher mGPS is associated with worse HRQL independent of PS. mGPS is simple, inexpensive and may be suitable for clinical practice, clinical trial patient selection and stratification.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Roncolato FT, Berton-Rigaud D, O'Connell R, et al. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol. 2017. PMID: 29107348. doi:10.1016/j.ygyno.2017.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。